Multimedia

Dr Long discusses her presentation at the Advances in Inflammatory Bowel Diseases regional meeting in Baltimore on the use of interleukin-12/23 and -23 inhibitors in the treatment of IBD.

Dr Cross, director of the IBD Program at the University of Maryland School of Medicine, discusses the key points from his presentation at the Advances in IBD regional meeting in Baltimore on using sphingosine 1-phosphate receptor modulators...

In this episode of IBD Drive Time, Dr Samir Shah talks with hosts Raymond Cross, MD, and Millie Long, MD, about his term as president of the American College of Gastroenterology, the addition of services that benefit both providers and...

Dr Cross, regional chair for the Advances in Inflammatory Bowel Disease, invites you to the in-person regional meeting in Baltimore March 31-April 1 -- and offers a discount on the registration fee!

Dr Holubar reviewed the key steps to preparing patients with inflammatory bowel disease for surgery to ensure the best possible outcomes at the Advances in Inflammatory Bowel Diseases virtual regional meeting April 20-21.

Dr. Mehandru reviews the results of 3 pivotal clinical trials on p19 inhibitors where the drug effect was found to be sustained for an extended period following drug withdrawal.

Dr Berinstein recaps his 'pitch' for the use of JAK inhibitors with corticosteroids to control acute severe ulcerative colitis, which he made to the "Shark Tank" panel at the Crohn's & Colitis Congress.

Dr Eisenstein reviews key reasons to involve a colorectal surgeon early in the care of patients with acute severe ulcerative colitis, rather than waiting until surgery has become a necessity.

In this episode of IBD Drive Time, host Raymond Cross, MD, talks with Asher Kornbluth, MD, about choosing and monitoring therapies for inflammatory bowel disease from among the growing number of options.

Dr Charabaty, from Johns Hopkins Sibley Memorial Hospital in Washington, DC, reviews her presentation from Advances in Inflammatory Bowel Disease 2022 on treating mild Crohn disease in adults and children.